BZPEERPapers, people, evidence and research paths
Menu

Discover

SearchFind papers, people, topics, institutions and opportunities from one place.GraphSee how papers, authors, topics and evidence connect.

Research tools

HomeContinue from the papers, people and topics that matter now.CollectionsTurn saved papers into reading lists, evidence maps and shareable context.ResearchReconstruct the path that led you from search to paper to question.CollaborationMove from a paper, topic or expert request into a focused thread.PublishCreate full-text research articles with metadata, formulas and versions.

Network

ExpertsFind specialists whose work and reviews explain why they can help.CommunitiesJoin research groups organized around papers, topics and shared evidence.

Opportunities

ListingsBrowse roles, calls and collaborations connected to real research context.

Account

Log inReturn to your saved papers, graph views and active threads.Create accountStart saving papers, building a research trail and joining teams.
Log inCreate account

Source author record

John Hargrove

John Hargrove appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record
ApplicationsPopulations and EvolutionQuantitative Methods

Catalog footprint

What is connected

2works
3topics
4close collaborators

Actions

Connect this record

Log in to claim
Open graphBrowse works

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2012arXiv

HIV/AIDS in South Africa: the beginning of the end?

In several countries in southern Africa, including South Africa, the prevalence of HIV remains stubbornly high in spite of considerable efforts to reduce transmission and to provide anti-retroviral therapy (ART). It is important to know the extent to which the high prevalence of HIV reflects the increasing number of people on ART in which case the prevalence of those not on ART may be falling. Unfortunately, direct measures of the proportion of HIV-positive people who are on ART are lacking in most countries and we need to use dynamical models to estimate the impact of ART on the prevalence of HIV. In this paper we show that the current level of ART provision in South Africa has probably reduced the prevalence of HIV among those not on ART by 1.9 million, averted 259 thousand new infections and 428 thousand deaths.

0 citations0 reviewsNo code linkedOpen access
preprint2012arXiv

Pre-exposure prophylaxis (PrEP) versus treatment-as-prevention (TasP) for the control of HIV: Where does the balance lie?

Anti-retroviral drugs can reduce the infectiousness of people living with HIV by about 96%--treatment as prevention or TasP--and can reduce the risk of being infected by an HIV positive person by about 70%--pre-exposure prophylaxis or PrEP--raising the prospect of using anti-retroviral drugs to stop the epidemic of HIV. The question as to which is more effective, more affordable and more cost effective, and under what conditions, continues to be debated in the scientific literature. Here we compare TasP and PreP in order to determine the conditions under which each strategy is favourable. This analysis suggests that where the incidence of HIV is less than 5% or the risk-reduction under PrEP is less than 50%, TasP is favoured over PrEP; otherwise PrEP is favoured over TasP. The potential for using PreP should therefore be restricted to those among whom the annual incidence of HIV is greater than 5% and TasP reduces transmission by more than 50%. PreP should be considered for commercial sex workers, young women aged about 20 to 25 years, men-who-have-sex with men, or intravenous drug users, but only where the incidence of HIV is high.

0 citations0 reviewsNo code linkedOpen access